Flexiroam Limited News - FRX

Richter To Start Late Stage Tests On Key Schizophrenia Drug

Hungarian drugmaker Richter Gedeon Nyrt. (RICHTER.BU) said Thursday it plans to move schizophrenia drug cariprazine into late-stage testing early...

Hungary Richter, US Forest Announce Positive Drug Tests

Hungarian drug maker Richter Gedeon Nyrt. (RICHTER.BU) and Forest Laboratories Inc. (FRX) announced positive drug test results on cariprazine...

Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce

-- Once-a-day tablet Daxas(R) (roflumilast) is a first-in-class treatment under development targeting inflammation, the underlying cause of...

2nd UPDATE: Glenmark, Forest Say Their Drug Failed In Trials

India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their experimental drug failed to...

UPDATE: Glenmark, Forest Say Oglemilast Failed In Key Study

India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their drug to treat a breathing...

AstraZeneca, Forest Labs Ink Ceftaroline Deal

U.K. pharmaceutical company AstraZeneca PLC (AZN.LN) Wednesday said it inked a deal to develop and sell an experimental anti-infection treatment...

Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD

NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- -- Forest Laboratories acquires exclusive commercialisation rights to Daxas in the United...

Forest Labs 1Q Net Up 8.2% As Namenda Sales Jump

Forest Laboratories Inc.'s (FRX) fiscal first-quarter profit rose a better-than-expected 8.2% as sales of its Namenda treatment for Alzheimer's...

Beacon Equity Research on Stocks to Watch: Forest Labs, Harris, Philip Morris, IAMGOLD, Steel Dynamics and Wyndham

DALLAS, June 22 /PRNewswire/ -- BeaconEquity.com announces the availability of stock alerts on today's active stocks. Stock alerts highlight...

Forest Labs Reports Upbeat Pneumonia Drug Test Results

Forest Laboratories Inc. (FRX) reported encouraging results from two late-stage studies of its ceftaroline treatment for bacterial pneumonia and...

PHARMA MARKET: Wyeth Stands By Pristiq After Slow Start

Sales of Wyeth's (WYE) new antidepressant Pristiq are nowhere near the drug maker's 2006 peak annual forecast of more than $2 billion, due to...

Drug Makers To Pay $89 Million To Settle Alabama Medicaid Price Suits

Pharmaceutical companies agreed to pay an additional $89 million to Alabama in settlement of litigation against 72 companies accused of defrauding...

2nd UPDATE:Jubilant Organosys Unit In Pact With AstraZeneca

Indian pharmaceutical company Jubilant Organosys Ltd. (530019.BY) Tuesday said a unit has signed a drug research agreement with the U.K.'s...

Almirall, Forest See New Drug Application For COPD By 2012

Spanish drug maker Laboratorios Almirall SA (ALM.MC) has started additional studies on a drug for chronic obstructive pulmonary disease, or COPD...

Forest Labs 4Q Net Drops 46% Amid Marketing Probe Set-Aside

Forest Laboratories Inc.'s (FRX) fiscal fourth-quarter net income fell 46%, partly reflecting $170 million the maker of name-brand and generic...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Flexiroam Limited (FRX)

Professional-Grade Tools, for Individual Investors.

FRX News

Richter To Start Late Stage Tests On Key Schizophrenia Drug

Hungary Richter, US Forest Announce Positive Drug Tests

Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce

2nd UPDATE: Glenmark, Forest Say Their Drug Failed In Trials

UPDATE: Glenmark, Forest Say Oglemilast Failed In Key Study

AstraZeneca, Forest Labs Ink Ceftaroline Deal

Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD

Forest Labs 1Q Net Up 8.2% As Namenda Sales Jump

Beacon Equity Research on Stocks to Watch: Forest Labs, Harris, Philip Morris, IAMGOLD, Steel Dynamics and Wyndham

Forest Labs Reports Upbeat Pneumonia Drug Test Results

PHARMA MARKET: Wyeth Stands By Pristiq After Slow Start

Drug Makers To Pay $89 Million To Settle Alabama Medicaid Price Suits

2nd UPDATE:Jubilant Organosys Unit In Pact With AstraZeneca

Almirall, Forest See New Drug Application For COPD By 2012

Forest Labs 4Q Net Drops 46% Amid Marketing Probe Set-Aside

FRX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Flexiroam Limited (FRX) News

Flexiroam Limited (FRX)

Professional-Grade Tools, for Individual Investors.

FRX News

Richter To Start Late Stage Tests On Key Schizophrenia Drug

Hungary Richter, US Forest Announce Positive Drug Tests

Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce

2nd UPDATE: Glenmark, Forest Say Their Drug Failed In Trials

UPDATE: Glenmark, Forest Say Oglemilast Failed In Key Study

AstraZeneca, Forest Labs Ink Ceftaroline Deal

Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD

Forest Labs 1Q Net Up 8.2% As Namenda Sales Jump

Beacon Equity Research on Stocks to Watch: Forest Labs, Harris, Philip Morris, IAMGOLD, Steel Dynamics and Wyndham

Forest Labs Reports Upbeat Pneumonia Drug Test Results

PHARMA MARKET: Wyeth Stands By Pristiq After Slow Start

Drug Makers To Pay $89 Million To Settle Alabama Medicaid Price Suits

2nd UPDATE:Jubilant Organosys Unit In Pact With AstraZeneca

Almirall, Forest See New Drug Application For COPD By 2012

Forest Labs 4Q Net Drops 46% Amid Marketing Probe Set-Aside

FRX Discussion

Your Recent History